Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203630 | 0.82 | KDM4E (0.62) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1458858 | 0.79 | KDM4E (0.55) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| Pyridine SCHEMBL9823801 | 0.74 | KDM4E (0.54) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3173950 | 0.74 | RARA (0.49) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL14777502 | 0.74 | KDM4E (0.51) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16990880 | 0.74 | KDM4E (0.54) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13801127 | 0.74 | KDM4E (0.63) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12116515 | 0.73 | ALDH1A1 (0.58) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30606304 | 0.73 | ALDH1A1 (0.58) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21474653 | 0.72 | KDM4E (0.53) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3033342-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | Grünenthal GmbH (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | GRUENENTHAL GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | GRUENENTHAL GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | GRUENENTHAL GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| WO-2015022073-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | Grünenthal GmbH (DE) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015022073-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | Grünenthal GmbH (DE) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151337-A1 | ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS | AADAC, PRRC2C, PRRC2A | KDM4E 2187/4885RAB9A 3307/4885NPC1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.